TBC1D3F Inhibitors
TBC1D3F inhibitors Wortmannin and LY294002, as PI3K inhibitors, can alter the downstream AKT signaling pathway, which plays a crucial role in regulating cell growth, survival, and metabolism. These changes in the AKT pathway can indirectly reduce the influence of TBC1D3F on these cellular processes. Similarly, inhibitors like Rapamycin, PD98059, and U0126 act on mTOR and MEK respectively, which are components of the PI3K/AKT/mTOR and MAPK/ERK pathways. These pathways are pivotal in controlling cell proliferation, differentiation, and response to external stimuli, processes that TBC1D3F might be a part of.
The other compounds, such as SB203580 and SP600125, target p38 MAPK and JNK, both of which are involved in the cellular stress response. By modulating these pathways, these inhibitors can affect TBC1D3F's potential role in mediating cellular responses to environmental challenges. Moreover, the inclusion of compounds like NSC23766, which targets Rac1, and Y-27632, a ROCK kinase inhibitor, highlights the possible connection of TBC1D3F with cytoskeletal organization and cell motility.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor, which can suppress downstream signaling pathways, including AKT signaling, that TBC1D3F may be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor capable of disrupting AKT pathway signaling, potentially affecting processes in which TBC1D3F is implicated. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can disrupt the PI3K/AKT/mTOR signaling axis, potentially altering TBC1D3F's role in cell growth and proliferation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor which can disrupt the MAPK/ERK pathway, affecting pathways that could be regulated by TBC1D3F. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor, which may alter the cellular responses to stress and inflammation where TBC1D3F may participate. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially modifying the JNK signaling pathway, which may impact TBC1D3F's function. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
A c-Raf kinase inhibitor that can impact the MAPK/ERK pathway, potentially affecting TBC1D3F's associated activities. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Disrupts Rac1 activation, which can affect cytoskeletal organization and cellular migration processes linked with TBC1D3F. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK kinase, potentially affecting actin cytoskeleton organization and TBC1D3F-related cell motility processes. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
An inhibitor of c-Raf kinase, which can affect MAPK/ERK signaling, potentially impacting TBC1D3F's activity in this pathway. | ||||||